We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00997152
First Posted: October 19, 2009
Last Update Posted: February 4, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Akros Pharma Inc.
October 14, 2009
October 19, 2009
February 4, 2013
September 2009
March 2010   (Final data collection date for primary outcome measure)
Change in Fasting Plasma Glucose (FPG) levels [ Time Frame: 3 months ]
Same as current
Complete list of historical versions of study NCT00997152 on ClinicalTrials.gov Archive Site
  • Change in glycosylated hemoglobin (HbA1c) levels [ Time Frame: 3 months ]
  • Effect on glycated albumin, insulin, C-peptide, glucagon and lipid parameters [ Time Frame: 3 months ]
  • Safety (biochemistry, hematology, urinalysis and adrenal-related markers) and tolerability (adverse events) [ Time Frame: 3 months ]
Same as current
Not Provided
Not Provided
 
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
A Phase II, Randomized, Double-Blind, Placebo-controlled, Multi-Center, Parallel Group Study Evaluating the Efficacy, Safety and Pharmacokinetics of JTT-654 Administered for 12 Weeks in Untreated or Metformin-treated Type 2 Diabetic Patients
The purpose of this study is to evaluate the effect of JTT-654 on diabetes as well as the safety, tolerability and pharmacokinetics of JTT-654 in type 2 diabetic patients.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Type II Diabetes Mellitus
  • Drug: JTT-654
    Tablets
  • Drug: JTT-654 Placebo
    Tablets
  • Experimental: Dose 1 JTT-654
    Intervention: Drug: JTT-654
  • Experimental: Dose 2 JTT-654
    Intervention: Drug: JTT-654
  • Placebo Comparator: Placebo
    Intervention: Drug: JTT-654 Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
152
April 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Have type 2 diabetes;
  2. Body mass index (BMI) of ≤ 45.0 kg/m2;
  3. Are either untreated with respect to hypoglycemic agents OR are currently being treated with a stable dose of metformin alone.

Exclusion Criteria:

  1. Females who are pregnant or breast-feeding;
  2. Known medical history or presence of type 1 diabetes or pancreatitis, acute metabolic diabetic complications, presence of unstable or rapidly progressing retinopathy, nephropathy or neuropathy;
  3. Acute coronary syndrome or uncontrolled hypertension;
  4. Does not meet all diet or previous/concomitant medication restrictions criteria, as described in the protocol.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00997152
AT654-U-09-004
No
Not Provided
Not Provided
Akros Pharma Inc.
Akros Pharma Inc.
Not Provided
Not Provided
Akros Pharma Inc.
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP